Compile Data Set for Download or QSAR
Report error Found 8 Enz. Inhib. hit(s) with Target = 'Plasma kallikrein' and Ligand = 'BDBM408768'
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408768(US10364238, Example 77 | N-[(6-cyano-2-fluoro-3-me...)
Affinity DataIC50: 0.600nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods. Human KLK1 (Callbiochem) was incubated at 25° C. with the fluoroge...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408768(US10364238, Example 77 | N-[(6-cyano-2-fluoro-3-me...)
Affinity DataIC50: 0.600nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408768(US10364238, Example 77 | N-[(6-cyano-2-fluoro-3-me...)
Affinity DataIC50: 0.600nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408768(US10364238, Example 77 | N-[(6-cyano-2-fluoro-3-me...)
Affinity DataIC50: 0.600nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/24/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408768(US10364238, Example 77 | N-[(6-cyano-2-fluoro-3-me...)
Affinity DataIC50: 0.600nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408768(US10364238, Example 77 | N-[(6-cyano-2-fluoro-3-me...)
Affinity DataIC50: 1nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408768(US10364238, Example 77 | N-[(6-cyano-2-fluoro-3-me...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408768(US10364238, Example 77 | N-[(6-cyano-2-fluoro-3-me...)
Affinity DataEC50:  5.5nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent